These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22207222)

  • 1. New regulatory framework for cancer drug development.
    Jones PS; Jones D
    Drug Discov Today; 2012 Mar; 17(5-6):227-31. PubMed ID: 22207222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unintended consequences of regulatory initiatives in childhood cancer drug development.
    Adamson PC
    JAMA Pediatr; 2013 Oct; 167(10):886-7. PubMed ID: 23938865
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development.
    Shea M; Ostermann L; Hohman R; Roberts S; Kozak M; Dull R; Allen J; Sigal E
    Nat Rev Drug Discov; 2016 Mar; 15(3):152. PubMed ID: 26931085
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Commission considers revisions to clinical trials directive.
    Mason E
    J Natl Cancer Inst; 2010 Mar; 102(5):292-4, 297. PubMed ID: 20173121
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug development in oncology: a regulatory perspective.
    Augustus S
    Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD; Saijo N; Seymour L; Calvert H
    Clin Cancer Res; 2010 Mar; 16(6):1737-44. PubMed ID: 20215555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Innovative Medicines Initiative: an engine for regulatory science.
    Goldman M; Seigneuret N; Eichler HG
    Nat Rev Drug Discov; 2015 Jan; 14(1):1-2. PubMed ID: 25503331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 0 trials for anticancer drug development.
    Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
    [No Abstract]   [Full Text] [Related]  

  • 10. Geriatric oncology: European Union regulatory perspectives and initiatives.
    Gravanis I
    J Geriatr Oncol; 2013 Apr; 4(2):202-4. PubMed ID: 24071546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European move affects academic trials research.
    Sinha G
    J Natl Cancer Inst; 2006 Aug; 98(16):1100-1. PubMed ID: 16912258
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of the European Clinical Trials Directive on published drug research in anaesthesia.
    Walker E; Hankins MC; White SM
    Anaesthesia; 2009 Sep; 64(9):984-9. PubMed ID: 19686484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and development of molecularly targeted drugs: regulatory perspectives.
    De Andres-Trelles F
    J Chemother; 2004 Nov; 16 Suppl 4():19-21. PubMed ID: 15688603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel anticancer agents and targets: recent advances and future perspectives.
    Barot KP; Nikolova S; Ivanov I; Ghate MD
    Mini Rev Med Chem; 2013 Jul; 13(9):1239-55. PubMed ID: 23746058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The drug development process: from target discovery to the clinic.
    Newell DR
    Clin Med (Lond); 2003; 3(4):323-6. PubMed ID: 12938745
    [No Abstract]   [Full Text] [Related]  

  • 16. Anticancer drug development: moving away from the old habits.
    Ades F; Zardavas D; Aftimos P; Awada A
    Curr Opin Oncol; 2014 May; 26(3):334-9. PubMed ID: 24614094
    [No Abstract]   [Full Text] [Related]  

  • 17. Too few medicines for children with cancer.
    Herold R; Saint-Raymond A; Norga K
    JAMA Pediatr; 2014 Jun; 168(6):583. PubMed ID: 24886801
    [No Abstract]   [Full Text] [Related]  

  • 18. European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287.
    Flavell DJ; Flavell SU; Sullivan R
    Lancet; 2003 Oct; 362(9393):1415. PubMed ID: 14585646
    [No Abstract]   [Full Text] [Related]  

  • 19. Too few medicines for children with cancer--reply.
    Adamson PC
    JAMA Pediatr; 2014 Jun; 168(6):583-4. PubMed ID: 24886802
    [No Abstract]   [Full Text] [Related]  

  • 20. [Development for and clinical trials of molecular targeting drugs].
    Takashima A; Fukuda H; Shibata T
    Gan To Kagaku Ryoho; 2010 May; 37(5):822-7. PubMed ID: 20524257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.